J A Cienfuegos1, J Baixauli2, F Rotellar2, J Arredondo3, J J Sola4, L Arbea5, C Pastor6, J L Hernández-Lizoáin2. 1. Department of General Surgery, Clínica Universidad de Navarra, School of Medicine, University of Navarra, Av. Pío XII, 36, 31008, Pamplona, Spain. fjacien@unav.es. 2. Department of General Surgery, Clínica Universidad de Navarra, School of Medicine, University of Navarra, Av. Pío XII, 36, 31008, Pamplona, Spain. 3. Department of General Surgery, Complejo Hospitalario de León, León, Spain. 4. Department of Pathology, Clínica Universidad de Navarra, School of Medicine, University of Navarra, Pamplona, Spain. 5. Department of Radiation Oncology, Clínica Universidad de Navarra, School of Medicine, University of Navarra, Pamplona, Spain. 6. Department of General Surgery, Fundación Jiménez Díaz, The Autonomous University of Madrid, Madrid, Spain.
Abstract
BACKGROUND AND OBJECTIVES: The standard treatment for locally advanced rectal cancer (LARC) is neoadjuvant chemoradiotherapy (CRT) followed by surgery. Pathological findings remain the most significant prognostic factor. The presence of mucin pools and their prognostic significance is a controversial issue. The aim of this study was to analyze the incidence of cellular and acellular mucin pools and their clinical significance. METHODS: Four-hundred and forty-six consecutive prospectively collected specimens from patients with LARC treated with long-course preoperative CRT and surgery were analyzed. Kaplan-Meier analysis was performed. RESULTS: Mucin pools were present in 182 specimens (40.8 %); 66 (14.7 %) were acellular, and viable tumor cells were identified in 116 (26 %). The complete pathological response rate was 13.5 % (60 of 446). With a median follow-up of 79.0 months, the 5- and 10-year disease-free survivals for patients with acellular and cellular mucin pools were 81.5, 78.1, 63.7 and 61.2 %, respectively (p ≤ 0.026). The presence of cells in the colloid response to treatment was associated with a 17.8 and 16.9 % decrease in 5- and 10-year disease survival vs. acellular colloid response. CONCLUSIONS: Our results suggest that cellular mucin pools are an indicator of an aggressive phenotype and harbingers of a worse prognosis.
BACKGROUND AND OBJECTIVES: The standard treatment for locally advanced rectal cancer (LARC) is neoadjuvant chemoradiotherapy (CRT) followed by surgery. Pathological findings remain the most significant prognostic factor. The presence of mucin pools and their prognostic significance is a controversial issue. The aim of this study was to analyze the incidence of cellular and acellular mucin pools and their clinical significance. METHODS: Four-hundred and forty-six consecutive prospectively collected specimens from patients with LARC treated with long-course preoperative CRT and surgery were analyzed. Kaplan-Meier analysis was performed. RESULTS:Mucin pools were present in 182 specimens (40.8 %); 66 (14.7 %) were acellular, and viable tumor cells were identified in 116 (26 %). The complete pathological response rate was 13.5 % (60 of 446). With a median follow-up of 79.0 months, the 5- and 10-year disease-free survivals for patients with acellular and cellular mucin pools were 81.5, 78.1, 63.7 and 61.2 %, respectively (p ≤ 0.026). The presence of cells in the colloid response to treatment was associated with a 17.8 and 16.9 % decrease in 5- and 10-year disease survival vs. acellular colloid response. CONCLUSIONS: Our results suggest that cellular mucin pools are an indicator of an aggressive phenotype and harbingers of a worse prognosis.
Entities:
Keywords:
Cellular mucin; Neoadjuvant chemoradiation; Outcome; Pathological response; Rectal cancer
Authors: Jose G Guillem; David B Chessin; Alfred M Cohen; Jinru Shia; Madhu Mazumdar; Warren Enker; Philip B Paty; Martin R Weiser; David Klimstra; Leonard Saltz; Bruce D Minsky; W Douglas Wong Journal: Ann Surg Date: 2005-05 Impact factor: 12.969
Authors: Leyo Ruo; Satish Tickoo; David S Klimstra; Bruce D Minsky; Leonard Saltz; Madhu Mazumdar; Philip B Paty; W Douglas Wong; Steven M Larson; Alfred M Cohen; Jose G Guillem Journal: Ann Surg Date: 2002-07 Impact factor: 12.969
Authors: Kerrington D Smith; Dongfeng Tan; Prajnan Das; George J Chang; Kiran Kattepogu; Barry W Feig; John M Skibber; Miguel A Rodriguez-Bigas Journal: Ann Surg Date: 2010-02 Impact factor: 12.969
Authors: Hak-Mien Quah; Joanne F Chou; Mithat Gonen; Jinru Shia; Deborah Schrag; Leonard B Saltz; Karyn A Goodman; Bruce D Minsky; W Douglas Wong; Martin R Weiser Journal: Cancer Date: 2008-07-01 Impact factor: 6.860
Authors: J A Cienfuegos; F Rotellar; J Baixauli; C Beorlegui; J J Sola; L Arbea; C Pastor; J Arredondo; J L Hernández-Lizoáin Journal: Ann Surg Oncol Date: 2014-09-05 Impact factor: 5.344